ELISA: 1: 1000approx. 1: 5000. WB: 1: 500approx. 1: 1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
Phosphate buffered saline (PBS), pH ~7.2, 15 mM Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
CEBPB
(CCAAT/enhancer Binding Protein (C/EBP), beta (CEBPB))
C/EBP β is a member of the C/EBP transcription factor family. The C/EBP β gene encodes several isoforms, which have truncated transcription activation domains by the alternative translational initiation at multipe AUG start sites. Initiation of translation at the in-frame AUGs forms four C/EBP β isoforms. C/EBP β is also known as interleukin 6-dependent DNA-binding protein (IL6DBP), liver activator protein(LAP) or liver-enriched transcriptional activator protein transcription factor 5 (TCF5). C/EBP β contributes to the regulation of the acute phase response in hepatocytes. Stat3 has an important function in IL-6-mediated transcription of the C/EBP β gene that has direct implication for acute phase response in liver cells.The 35 kDa C/EBP β form requires phosphorylation for its DNA binding ability, and increased binding of C/EBP β isoforms during acute-phase reaction occurs through its upregulation and structural modification.Synonyms: C/EBP beta, CCAAT/enhancer-binding protein beta, LAP, Liver activator protein, NF-IL6, Nuclear factor NF-IL6, TCF5, Transcription factor 5